Dr. Leonard on Ibrutinib Combined With Chemotherapy in Follicular Lymphoma

John P. Leonard, MD
Published: Thursday, Aug 20, 2015



John P. Leonard, MD, medical oncology, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, discusses the phase III SELENE study, which is examining the addition of ibrutinib to either R-CHOP or bendamustine plus rituximab for the treatment of patients with follicular lymphoma (FL).

Ibrutinib is described as a Bruton's tyrosine kinase inhibitor that is active and approved for select patients with mantle cell lymphoma and chronic lymphocytic leukemia. It also demonstrates activity in patients with FL and other indolent lymphomas.

Ibrutinib is being examined with the chemotherapy regimens in patients with relapsed/refractory FL or other indolent lymphomas in the SELENE trial, which hopes to improve progression-free survival. Ideally, researchers hope the combination will be associated with limited toxicities and improve overall survival and quality of life for patients.

SELECTED
LANGUAGE


John P. Leonard, MD, medical oncology, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, discusses the phase III SELENE study, which is examining the addition of ibrutinib to either R-CHOP or bendamustine plus rituximab for the treatment of patients with follicular lymphoma (FL).

Ibrutinib is described as a Bruton's tyrosine kinase inhibitor that is active and approved for select patients with mantle cell lymphoma and chronic lymphocytic leukemia. It also demonstrates activity in patients with FL and other indolent lymphomas.

Ibrutinib is being examined with the chemotherapy regimens in patients with relapsed/refractory FL or other indolent lymphomas in the SELENE trial, which hopes to improve progression-free survival. Ideally, researchers hope the combination will be associated with limited toxicities and improve overall survival and quality of life for patients.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x